Nippon Chemical Industrial (4092) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 of the fiscal year ending March 2026, the Company reported lower revenue and lower profit, with deteriorating profitability in the Functional Products Business weighing down company-wide earnings. Revenue was ¥304.4B (down -1.4% YoY), Operating Income was ¥19.9B (down -40.7%), Ordinary Income was ¥19.8B (down -41.2%), and Net Income was ¥18.4B (down -21.8%). The Operating Income margin was 6.5%, substantially below approximately 10.9% in the same period of the previous year. The relatively smaller decline in Net Income was attributable to the boost from extraordinary income of ¥5.3B, including a gain on the sale of fixed assets of ¥5.0B.

Factors Affecting Results

【Revenue】Revenue was ¥304.4B, nearly flat with a 1.4% year-on-year decline. By segment, the Functional Products Business increased revenue to ¥159.9B (up +2.3%), and the Rental Business increased revenue to ¥7.0B (up +2.6%), while the core Chemicals Business reported lower revenue of ¥135.2B (down -3.0%). Although the Functional Products Business drove revenue growth, this was accompanied by the deterioration in profitability described below, and the quality of the revenue growth cannot be considered favorable.

【Profit and Loss】Operating Income was ¥19.9B (down -40.7%), and Ordinary Income was ¥19.8B (down -41.2%), indicating that the deterioration at the operating level was almost fully reflected at the ordinary income level. The factors are clear when viewed by segment: profit in the Chemicals Business declined 15.1%, while profit in the Functional Products Business declined 73.0%, causing the Functional Products Business margin to fall sharply from approximately 10.3% in the previous year to 2.7%. The Rental Business maintained a high Operating Income margin of 58.8%, providing support to overall earnings. Net Income of ¥18.4B (down -21.8%) was driven by extraordinary income of ¥5.3B, including a gain on the sale of fixed assets of ¥5.0B, exceeding extraordinary losses of ¥1.9B and boosting profit before tax. This was a decline in both revenue and profit, with the decline in profit exceeding the decline in revenue; the primary cause was the structural deterioration in the profitability of the Functional Products Business.

Segment Analysis

The Chemicals Business reported Revenue of ¥135.2B (down -3.0%) and Operating Income of ¥10.9B (down -15.1%), making it the core business and accounting for 55.0% of total segment profit. The Functional Products Business increased revenue to ¥159.9B (up +2.3%), but Operating Income fell to ¥4.3B (down -73.0%), causing its margin to decline approximately 760bp from approximately 10.3% in the previous year to 2.7%. Despite higher revenue, profit declined substantially, suggesting deterioration in pricing, product mix, or costs. The Rental Business reported Revenue of ¥7.0B (up +2.6%) and Operating Income of ¥4.1B, with a stable margin of 58.8%, thereby supporting company-wide profit.

Key Financial Metrics

【Profitability】The Operating Income margin was 6.5%, down approximately 4.3pt year on year, while the Net Income margin was 6.0%. However, the Net Income margin includes the contribution of extraordinary income, primarily the gain on the sale of fixed assets, and therefore does not represent recurring earnings power.【Cash Flow Quality】The CCC calculated from DSO of 101 days and DIO of 133 days was equivalent to 182 days, indicating that working capital remains tied up in accounts receivable and inventory for an extended period.【Investment Efficiency】ROE was 3.8%, and the total asset turnover ratio remained at 0.388x, indicating a level at which there remains room to improve profit generation from invested capital.【Financial Soundness】The Equity Ratio was 61.5%, and the current ratio was approximately 148.0%, indicating a strong capital base. However, short-term borrowings account for a large portion of interest-bearing debt, and cash and deposits of ¥85.6B were below short-term borrowings of ¥128.3B.

Cash Flow Analysis

Although the cash flow statement was not disclosed, the trends in the balance sheet indicate that cash and deposits increased to ¥85.6B from ¥79.3B in the same period of the previous year, while trade receivables increased to ¥112.3B (¥89.9B in the previous year), and inventories remained nearly flat but high at ¥46.3B. DSO of 101 days and DIO of 133 days suggest that working capital is expanding despite flat revenue, raising the possibility that the collection speed of funds generated from operating activities has slowed. Short-term borrowings increased to ¥128.3B, suggesting that the accumulation of working capital is one factor increasing reliance on short-term financing. Property, plant and equipment was nearly flat at ¥343.5B, with no significant expansion in investment confirmed.

Quality of Earnings

Pre-tax profit of ¥23.1B included extraordinary income of ¥5.3B, primarily consisting of a gain on the sale of fixed assets of ¥5.0B, and extraordinary losses of ¥1.9B, primarily consisting of a loss on disposal of fixed assets of ¥1.4B, resulting in a net boost to profit of ¥3.4B. The net amount of these one-time items was equivalent to 18.5% of Net Income of ¥18.4B, and attention should be paid to the fact that Net Income was boosted beyond the level of recurring earnings power. Non-operating income and expenses were nearly balanced, with income of ¥2.2B against expenses of ¥2.3B; interest expense of ¥1.1B was the primary expense item. Comprehensive income was ¥27.0B, exceeding Net Income of ¥18.4B, primarily due to an increase of ¥10.5B in valuation differences on available-for-sale securities, while adjustments related to retirement benefits were negative ¥2.1B. In assessing the earnings power of the core business, it is necessary to monitor trends in profit at the ordinary income level excluding extraordinary income.

Earnings Forecast and Guidance

The full-year company forecast is Revenue of ¥405.0B (up +4.3% YoY), Operating Income of ¥32.0B (down -4.3%), and Ordinary Income of ¥32.0B. The Q3 cumulative progress rate was 75.2% for Revenue, a standard level, while the progress rate for Operating Income was only 62.1%, 12.9pt below the standard benchmark of 75%. To achieve the forecast, approximately ¥12.1B of Operating Income would be required in Q4 alone, substantially above the quarterly average of ¥6.6B for the Q3 cumulative period. The progress rate toward the Net Income forecast of ¥26.0B was 70.6%, higher than that for Operating Income, largely due to the contribution of the gain on the sale of fixed assets included in the Q3 cumulative results. Accordingly, the extent of recovery in core operating margins, particularly in the Functional Products Business, will be the key to achieving the full-year forecast from Q4 onward.

Shareholder Returns

The Q2 dividend was ¥60.00 per share, and the full-year dividend forecast is ¥120.00 (assumed interim dividend of ¥60.00 and year-end dividend of ¥60.00). Based on the number of shares outstanding, the full-year total dividend amount is approximately ¥10.7B, and the forecast Payout Ratio against the full-year Net Income forecast of ¥26.0B is approximately 41.2%, below the general benchmark of 60%. Using Q3 cumulative Net Income of ¥18.4B, the Payout Ratio for the Q2 dividend portion is 29.2%. The execution status of share repurchases has not been disclosed, and this section evaluates the Payout Ratio based solely on dividends.

Risk Factors

1. Deterioration in the profitability of the Functional Products Business: Revenue increased to ¥159.9B (up +2.3%), but segment profit declined sharply to ¥4.3B (down -73.0%), causing the margin to fall to 2.7%. This was the primary cause of the company-wide decline in Operating Income, and delays in improving price pass-through, product mix, or cost management could place pressure on achieving the full-year profit forecast.

2. Working capital accumulation and refinancing structure: Working capital equivalent to 182 days based on CCC is tied up, with DSO of 101 days and DIO of 133 days. Short-term borrowings account for approximately 80% of interest-bearing debt, and cash and deposits of ¥85.6B are below short-term borrowings of ¥128.3B, requiring monitoring of the financing structure.

3. Impact of chemical market conditions and raw material and fuel costs: In the core Chemicals Business, profit declined 15.1% against a 3.0% decline in Revenue to ¥135.2B, indicating that profit contracted more than revenue and suggesting sensitivity to raw material, fuel, and energy costs as well as changes in supply and demand.

Industry Benchmarks (For Reference; Compiled by the Company)

Industry Benchmarks (manufacturing)

Profitability and Return

Both the Operating Income margin and Net Income margin are below the industry median, positioning the Company somewhat behind its industry peers in terms of profitability.

Growth and Capital Efficiency

The Revenue growth rate was 4.7pt below the industry median, indicating that the Company also lags its industry peers in top-line growth.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The core Chemicals Business reported Operating Income of ¥10.9B, accounting for 55.0% of total segment profit, but profit declined 15.1% year on year, indicating a slowdown in part of the earnings foundation.

2. Although the Functional Products Business increased revenue, its Operating Income margin fell sharply to 2.7%, making the recovery of profitability in this business a key point to monitor as it will influence future earnings trends.

3. The progress rate toward the full-year Operating Income forecast was 62.1%, below the standard benchmark of 75%. Since Q3 cumulative Net Income includes a gain on the sale of fixed assets, trends in core earnings power excluding one-time items will need to be confirmed.

Theoretical Share Price (Reference Value)

Sensitivity: ¥4,775–¥5,050 at Cost of Equity ±1%, and ¥4,890–¥4,922 at ω±0.1.

Notes:

• As forecast ROE is below the Cost of Equity, the theoretical value is below Book Value per Share.
• Net assets at the end of the quarter are used (there is a timing gap relative to the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson type; explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation to take any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 earnings were operationally weak, with a modest sales decline accompanied by a sharp contraction in profitability, although asset-sale gains cushioned reported net income. Cumulative revenue for the first nine months was ¥30.44bn, down 1.4% year on year. Operating income fell 40.7% to ¥1.99bn, substantially underperforming the movement in sales. Ordinary income declined 41.2% to ¥1.98bn. Net income attributable to owners decreased by a less severe 21.8% to ¥1.84bn because extraordinary gains lifted pre-tax profit. The gross margin contracted 365bp year on year to 20.3%, from 23.9% in the comparable period. The operating margin fell 433bp to 6.5%, from 10.9%, reflecting the gross-profit decline and a 69bp increase in the SG&A-to-sales ratio to 13.8%. Net margin declined by 157bp to 6.0%, but this understates the deterioration in recurring profitability because ¥5.04bn of gains on fixed-asset sales were recorded in extraordinary income. Net extraordinary gains were ¥3.40bn after ¥1.94bn of extraordinary losses, equivalent to 34.9% of reported net income under the supplied quality alert. The chemical products business remained profitable but saw both sales and segment profit decline. The functional products business delivered modest sales growth but experienced a severe decline in segment profit, making it the principal source of consolidated earnings pressure. The rental business remained a stable, high-margin earnings contributor despite its small revenue base. Balance-sheet liquidity remains adequate, with a 148.0% current ratio and 127.3% quick ratio. However, ¥12.83bn of short-term borrowings represent 79.5% of interest-bearing debt, creating a meaningful refinancing and maturity-management consideration. Capital efficiency is subdued, with reported annualized ROE of 5.1% and a supplied ROIC of 3.8%, both below the stated return benchmarks. Working-capital intensity is elevated, as indicated by supplied annualized DSO of 101 days, DIO of 133 days, and a 182-day cash-conversion cycle. Management maintained full-year guidance, but Q3 operating-income progress of 62.1% is 12.9 percentage points below the normal 75% seasonal benchmark, implying a materially stronger final quarter is required.

Profitability Analysis

Reported annualized ROE is 5.1%, decomposed into a 6.0% net profit margin, 0.518x annualized asset turnover, and 1.63x financial leverage. The largest adverse movement is profitability rather than leverage: the operating margin compressed 433bp year on year to 6.5%, while the gross margin fell 365bp to 20.3%. Revenue declined only 1.4%, whereas gross profit decreased 16.4% to ¥6.17bn and operating income fell 40.7% to ¥1.99bn, indicating substantial negative operating leverage. SG&A expense rose 3.8% to ¥4.19bn despite the revenue decline, lifting the SG&A ratio to 13.8% from 13.1%. This cost-sales mismatch amplified the gross-margin pressure. The five-factor DuPont data show a normal tax burden of 0.793 and strong interest coverage of 17.28x, so tax and financing costs are not the core reason for weak operating performance. The interest burden of 1.165 reflects extraordinary gains increasing profit before tax above EBIT, rather than a recurring financing advantage. Reported net income includes a ¥5.04bn gain on sales of fixed assets and a ¥0.29bn gain on sales of investment securities, offset partly by ¥1.36bn of fixed-asset disposal losses and other extraordinary losses. Accordingly, ordinary income of ¥1.98bn is the more relevant indicator of recurring earnings than net income of ¥1.84bn. The supplied 3.8% ROIC alert is consistent with returns that remain below the estimated cost of capital threshold generally required for value creation. Financial leverage of 1.63x is moderate and does not indicate that the company is using excessive balance-sheet leverage to support ROE.

Growth Assessment

Revenue resilience was mixed across businesses. Chemical products revenue declined 3.0% year on year to ¥13.52bn, while segment profit fell 15.1% to ¥1.09bn. Functional products revenue rose 2.3% to ¥15.99bn, but segment profit plunged 73.0% to ¥0.43bn, reducing its segment margin to 2.7% from 10.3%. This divergence suggests that pricing, product mix, input costs, utilization, or competitive conditions in functional products weakened materially despite revenue growth. Rental revenue increased 2.6% to ¥0.70bn and segment profit increased 0.7% to ¥0.41bn; its segment margin of 58.8% makes it the highest-margin business, though its scale is limited. Chemical products generated the largest segment-profit contribution at ¥1.09bn and is therefore the core business by operating-income contribution. Other businesses generated revenue of ¥2.30bn, down 62.8% year on year, while segment profit was broadly stable at ¥0.26bn. The full-year forecast calls for revenue of ¥40.50bn, operating income of ¥3.20bn, and net income of ¥2.60bn. Q3 cumulative progress is 75.2% for revenue, broadly in line with the 75% seasonal reference point. Operating-income progress is only 62.1%, 12.9 percentage points below the reference point, while net-income progress is 70.6%, 4.4 percentage points below it. Achieving guidance requires Q4 revenue of ¥10.06bn, operating income of ¥1.21bn, and net income of ¥0.77bn. The implied Q4 operating margin is approximately 12.1%, versus 6.5% for the first nine months, requiring a significant sequential recovery in gross margin and/or fixed-cost absorption. The forecast also assumes full-year revenue growth of 4.3% but a 4.3% decline in operating income, indicating management itself expects margins to remain below the prior-year level.

Financial Health

Liquidity is adequate on reported balance-sheet metrics: current assets of ¥33.19bn exceed current liabilities of ¥22.43bn, producing a 148.0% current ratio. The 127.3% quick ratio indicates that liquidity coverage does not depend heavily on inventory liquidation. Working capital totals ¥10.76bn, and cash and deposits are ¥8.56bn. Total interest-bearing debt is ¥16.14bn, comprising ¥12.83bn of short-term loans and ¥3.31bn of long-term loans. The debt-to-equity ratio is a moderate 0.63x, while debt-to-capital is 25.1%, both within conservative covenant-style benchmarks. Interest coverage of 17.28x indicates that current operating earnings provide substantial coverage of interest expense. The key financial-risk flag is the 79.5% short-term debt ratio: short-term borrowings increased ¥2.25bn year on year to ¥12.83bn, while long-term loans declined ¥1.19bn to ¥3.31bn. This concentration increases refinancing exposure and requires reliable access to bank facilities or capital markets. Current assets remain larger than short-term borrowings, and the current ratio is above 1.0, so there is no immediate maturity mismatch warning; nevertheless, the debt maturity profile is less resilient than the aggregate liquidity ratios alone imply. Investment securities increased ¥1.50bn, or 33.0%, to ¥6.05bn, increasing exposure to market valuation movements. Total equity increased ¥1.81bn to ¥48.21bn, supported by retained earnings and positive other comprehensive income. Comprehensive income of ¥2.70bn exceeded net income by ¥0.86bn, principally reflecting a ¥1.05bn positive valuation difference on securities, which also makes equity partly sensitive to securities-market movements.

Notable B/S Changes

Investment securities: +¥1.50bn (+33.0%) to ¥6.05bn - increased exposure to market valuation movements; positive securities valuation changes also supported other comprehensive income. Accounts payable: +¥1.05bn (+29.6%) to ¥4.61bn - supplier financing increased, partly offsetting working-capital needs, but should be viewed alongside the elevated receivable and inventory days. Long-term loans: -¥1.19bn (-26.4%) to ¥3.31bn - long-term debt reduction is positive in isolation, but the simultaneous increase in short-term loans has increased refinancing concentration. Short-term loans: +¥2.25bn (+21.3%) to ¥12.83bn - short-term funding now accounts for 79.5% of interest-bearing debt, elevating refinancing risk. Trade receivables: +¥2.25bn (+25.0%) to ¥11.23bn - the increase materially exceeds the revenue trend and is consistent with the supplied 101-day annualized DSO warning.

Cash Flow Quality

The supplied working-capital alerts point to elevated cash-conversion risk. Annualized DSO of 101 days is well above the 60-day warning threshold, indicating slow collection or a customer and contract mix that ties up substantial capital in receivables. Trade receivables increased 25.0% year on year to ¥11.23bn, substantially outpacing the 1.4% revenue decline. Annualized DIO of 133 days is also above the 90-day warning threshold and indicates high inventory funding requirements for a chemical manufacturer. The supplied annualized cash-conversion cycle of 182 days is above the 120-day warning threshold, raising the likelihood that operating cash generation may lag accounting earnings during periods of working-capital build. Accounts payable increased 29.6% to ¥4.61bn, providing some supplier-financing offset to receivables, but not enough to eliminate the long cash cycle indicated by the supplied metrics. The combination of higher receivables, high inventory days, and a long cash-conversion cycle should be monitored for collection discipline, demand normalization, inventory obsolescence, and production-planning efficiency. Reported earnings quality is also reduced by the large non-recurring asset-sale gain: net extraordinary gains of ¥3.40bn supported pre-tax profit, and supplied one-time items represent 34.9% of net income. Recurring ordinary income of ¥1.98bn is therefore a more conservative basis for evaluating cash-generative earning power than reported net income.

Dividend Sustainability

The company paid an interim Q2 dividend of ¥60 per share and forecasts a full-year dividend of ¥120 per share. Based on forecast EPS of ¥297.63, the forecast dividend payout ratio is approximately 40.3%, which is below the 60% sustainability benchmark. The supplied cumulative payout-ratio calculation is 29.2%, based on the ¥60 interim dividend relative to nine-month net income. Retained earnings of ¥346.17bn and total equity of ¥482.09bn provide substantial accounting capital support for the distribution policy. The principal consideration is not the nominal payout ratio but the weaker recurring operating income and the elevated working-capital cycle. Because reported Q3 net income was supported by non-recurring gains on asset sales, dividend coverage should be assessed primarily against the full-year earnings outlook and recurring cash generation rather than nine-month reported net income. No share buyback information is provided; therefore, the analysis refers only to the dividend payout ratio and not a total return ratio. Maintaining the forecast dividend requires delivery of the forecast full-year earnings target, including the implied Q4 operating recovery.

Risk Assessment

Business risks include Functional products is the highest-priority operating risk: revenue increased 2.3% to ¥15.99bn, yet segment profit fell 73.0% to ¥0.43bn and margin declined from 10.3% to 2.7%. This indicates acute pressure from price, mix, raw-material costs, utilization, or competition., For a chemical manufacturer, volatility in raw-material, energy, and logistics costs can further pressure margins when selling-price pass-through is incomplete. The 365bp gross-margin decline makes this risk material., Chemical products revenue declined 3.0% and segment profit declined 15.1%, showing that the core profit contributor is also experiencing demand or margin pressure., The supplied 133-day annualized inventory period raises risk of slow-moving stock, valuation pressure, and production adjustments if demand weakens..

Financial risks include REFINANCING_RISK: 79.5% of interest-bearing debt is short term, with ¥12.83bn of short-term loans. This is concerning because frequent refinancing exposes the company to lender terms and interest-rate changes. Aggregate liquidity is adequate, but reducing short-term funding concentration would improve resilience., HIGH_RECEIVABLE_DAYS: supplied annualized DSO of 101 days exceeds the 60-day warning level. Receivables rose 25.0% while revenue declined, which can delay cash realization and increase counterparty-credit exposure., HIGH_INVENTORY_DAYS: supplied annualized DIO of 133 days exceeds the 90-day warning level. High inventory is particularly consequential in chemicals because product demand, raw-material prices, and product specifications can change., LONG_CCC: the supplied 182-day annualized cash-conversion cycle exceeds the 120-day warning level. The long operating funding cycle can increase dependence on short-term borrowings., Investment securities increased 33.0% to ¥6.05bn, and positive securities valuation changes contributed to comprehensive income; this introduces market-value sensitivity into equity..

Key concerns include CAPITAL_EFFICIENCY: supplied ROIC of 3.8% is below the 5% warning threshold. This weak return profile, together with 5.1% annualized ROE, limits the margin for capital-allocation errors and makes margin recovery important., HIGH_ONE_TIME_ITEMS: supplied one-time items equal 34.9% of net income. The root cause is principally the ¥5.04bn gain on sale of fixed assets, net of extraordinary losses. This improves reported profit but is not a recurring source of earnings, so the investment thesis should emphasize ordinary income and segment-margin recovery., The operating-income forecast requires an implied Q4 operating margin of about 12.1%, nearly double the 6.5% nine-month margin. Execution risk is therefore elevated., The 433bp operating-margin decline and 73.0% profit decline in functional products indicate that a recovery in revenue alone may not restore earnings without improved pricing, mix, costs, or utilization..

Investment Implications

Key takeaways include Revenue is broadly stable, but earnings have deteriorated sharply because of gross-margin compression and unfavorable operating leverage., Recurring profitability is weaker than reported net income suggests because extraordinary asset-sale gains supported pre-tax income., Chemical products is the core business by segment profit, while functional products is the main source of earnings volatility in the current period., Liquidity and leverage are manageable, but the short-term debt concentration and long operating cash cycle raise funding-discipline requirements., The unchanged full-year forecast depends on a substantial Q4 operating recovery..

Metrics to watch include Functional products segment margin and profit recovery, Consolidated gross margin and SG&A-to-sales ratio, Q4 operating income versus the ¥1.21bn implied by full-year guidance, Annualized DSO, DIO, and cash-conversion cycle, Short-term loan balance, refinancing terms, and interest expense, Investment-securities valuation movements and their effect on equity, Recurring ordinary income excluding extraordinary gains.

Regarding relative positioning, The company has a sounder balance-sheet profile than highly leveraged manufacturers, supported by a 0.63x debt-to-equity ratio, 25.1% debt-to-capital ratio, and 17.28x interest coverage. However, its 5.1% annualized ROE and supplied 3.8% ROIC are below standard capital-efficiency thresholds, while the 6.5% operating margin is below the stated 8% level associated with stronger profitability. Its long supplied 182-day annualized cash-conversion cycle is also less efficient than manufacturing benchmarks.